Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces the appointment of Jim MacDonald-Clink as Vice President, Business Development with immediate effect.
Arecor strengthens management team to accelerate partnership opportunities
Jim, who joins the Arecor Leadership team from Mundipharma, will be responsible for extending and expanding areas of growth. At Mundipharma, Jim was responsible for Business Development and established the biosimilar platform and oncology strategy via acquisition and licensing agreements. His experience includes acquisition, licensing and strategic partnering initiatives in specialist therapy areas as well as various roles in R&D, Medical and Commercial functions.
Jim has over 25 years of experience in healthcare with Mundipharma, Astellas Pharma, Fujisawa, Institute of Cancer Research at the Royal Marsden and Institute of Child Health at Great Ormond Street Hospital, London, UK. Jim holds a degree in Medicinal Chemistry.
Sarah Howell, Chief Executive Officer at Arecor, said: " We are delighted to welcome Jim to Arecor at a pivotal time in our evolution. He brings 25 years of experience and expertise in business development within the pharma industry, as well as in the broader areas of pharma development and commercialisation. Jim will play a key role in delivering our strategic business development plans as we strive to meet our ambitious goal of transforming patient care by bringing innovative medicines to market using our Arestat™ technology.”
Advancing today's therapies to enable healthier lives.